A Multicenter Cancer Biospecimen Collection Study

Description

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Conditions

Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Colorectal Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor biopsy. These specimens and clinical data may be used in subsequent studies for the development and validation of a diagnostic test.

Predicting Immunotherapy Efficacy From Analysis of Pre-treatment Tumor Biopsies

A Multicenter Cancer Biospecimen Collection Study

Condition
Cancer of Head and Neck
Intervention / Treatment

-

Contacts and Locations

San Francisco

Curebase, San Francisco, California, United States, 94131

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Subject must have a disease of interest. Specifically, subject must have one of:
  • 1. head and neck squamous cell carcinoma (HNSCC)
  • 2. non-small-cell lung cancer (NSCLC)
  • 3. small cell lung cancer (SCLC)
  • 4. urothelial carcinoma (UCC)
  • 5. gastric or gastroesophageal junction adenocarcinoma
  • 6. cervical cancer
  • 7. esophageal squamous cell carcinoma (ESCC)
  • 8. triple-negative breast cancer (TNBC)
  • 9. hepatocellular carcinoma (HCC)
  • 10. renal cell carcinoma (RCC)
  • 11. colorectal cancer (CRC)
  • 2. Subject must have received, or be scheduled to receive, at least one dose of anti-PD-1/PD-L1 immunotherapy for treatment of their cancer.
  • 3. Subject must have had, or will have, a tumor biopsy prior to treatment with anti-PD-1/PD-L1 immunotherapy.
  • 4. Subject must have undergone, or will undergo, medical imaging (e.g. CT or MRI) of the tumor prior to treatment with anti-PD-1/PD-L1 immunotherapy.
  • 5. Willing to provide electronic informed consent per IRB-approved protocol.
  • 6. Able to speak, read, and comprehend English fluently.
  • 7. Subject is 18 years of age or older.
  • 8. Subjects must have sufficient tissue available to fulfill the specimen requirements of the study.
  • 1. Inability or unwillingness to provide informed consent.
  • 2. Subject who does/did not have one of the cancers listed above (other histologies).
  • 3. Subject has already participated in this trial.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cofactor Genomics, Inc.,

Jarret Glasscock, STUDY_DIRECTOR, Cofactor Genomics

Study Record Dates

2027-02